Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) followed by Isoniazid, Rifampicin (HR) Regimen

Treatment for Hiv Aids Drug Susceptible Tuberculosis

Typical Dosage: Weight-based daily or thrice-weekly dosing for Isoniazid, Rifampicin, Pyrazinamide, Ethambutol

Effectiveness

90%

Safety Score

60%

Clinical Trials

5,000

Participants

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Treatment Details

Dosage Range

Weight-based daily or thrice-weekly dosing for Isoniazid, Rifampicin, Pyrazinamide, Ethambutol

Time to Effect

1-2 weeks for clinical improvement, 2-4 weeks for sputum conversion

Treatment Duration

6 months (2 months intensive, 4 months continuation)

Evidence Quality

HIGH

Number Needed to Treat (NNT)

1(Treat 1 patients to see 1 additional successful outcome)

Number Needed to Harm (NNH)

20(Treat 20 patients to see 1 additional serious adverse event)

Confidence Score

95%confidence in effectiveness data

Health Economics

Annual Cost of Care

Drug Cost:$680

Monitoring:$2,300

Side Effect Mgmt:$350

Total Annual:$3,330

Cost-Effectiveness Analysis

Cost-Effectiveness Rating

EXCELLENT

ICER

$8,000/QALY

QALYs Gained

Outcome-Based Costs

Cost per Responder

$3,700

Cost per Remission

$3,918

Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) followed by Isoniazid, Rifampicin (HR) Regimen Outcomes

for Hiv Aids Drug Susceptible Tuberculosis

Efficacy Outcomes

Overall Effectiveness

+90%

Response Rate

+90%

Remission Rate

+85%

Common Side Effects

Hepatotoxicity (elevated LFTs, hepatitis)

+8%

Peripheral neuropathy

+5%

Gastrointestinal upset (nausea, vomiting, abdominal pain)

+15%

Orange/red discoloration of urine/tears/sweat

+99%

Arthralgia

+15%

Optic neuritis

+3%

Rash

+3%

Sources:

nih.gov

atsjournals.org

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials

1 active trial recruiting for Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) followed by Isoniazid, Rifampicin (HR) Regimen in Hiv Aids Drug Susceptible Tuberculosis

Rifapentine-Based Shorter Regimens for Tuberculosis and TB Infection in Kazakhstan

NCT07668479NOT YET RECRUITING

View Study

350 participants

OBSERVATIONAL

Started: Jul 1, 2026